Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model

By sjmartinez • October 16, 2023

Iannone V, Babu AF, Lok J, Gómez-Gallego C, D'Auria G, Vazquez-Uribe R, Vaaben TH, Bongers M, Mikkonen S, Vaittinen M, Tikkanen I, Kettunen M, Klåvus A, Sehgal R, Kaminska D, Pihlajamaki J, Hanhineva K, El-Nezami H, Alexander Sommer MO, Kolehmainen M. Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model. Mol Metab. 2023 Oct 13:101823. doi: 10.1016/j.molmet.2023.101823. Epub ahead of print. PMID: 37839774.

Tags: aldafermin, Cardiology/Epi, genetically modified E. coli Nissle 1917, Metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, non-targeted metabolomics, omics integration, Publications, Transcriptomics

Related Posts

Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort

Tang GHL, Hahn RT, Whisenant BK, Hamid N, Naik H, Makkar RR, Tadros P, Price MJ, Singh GD, Fam NP, Kar S, Mehta SR, Bae[...]

Mobile Stroke Unit Management in Patients With Acute Ischemic Stroke Eligible for Intravenous Thrombolysis

Mac Grory B, Sun JL, Alhanti B, Lusk J, Li F, Adeoye O, Furie K, Hasan D, Messe S, Sheth KN, Schwamm LH, Smith EE,[...]

Trends and Disparities in Coronary Artery Disease and Obesity-Related Mortality in the United States From 1999-2022

Ahmed M, Javaid H, Shafiq A, Nadeem ZA, Ahsan A, Nofal A, Ahmed R, Alam M, Fudim M, Fonarow GC, Mamas MA. Trends and Disparities[...]